-
FDA Receives sNDA for Relacorilant in Platinum-Resistant Ovarian Cancer
15 Jul 2025 21:14 GMT
… has been submitted to the FDA, according to a news release … phase 2 trials: the completed phase 2 CORT125134-552 trial (NCT03776812), which … bevacizumab (Avastin).
Corcept submits new drug application for relacorilant as a treatment for …
-
Evaluating Efficacy of Second-Line RCC Treatments Post-Immunotherapy
15 Jul 2025 13:04 GMT
… in the Department of Medical Oncology & Therapeutics … guidelines for second-line treatments, while emphasizing the … ], sunitinib [Sutent], bevacizumab [Avastin], etc, but these come … pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer …
-
Ovarian Cancer Drugs Market to Hit $7.2 Billion by 2035, Driven by Rising FDA Approvals and 2024's $4.2 Billion Base
14 Jul 2025 07:02 GMT
… for the ovarian cancer treatment drugs market with robust … Phase 3 trial that supports the medicine as a … FDA approval for Jobevne (bevacizumab-nwgd), a biosimilar to Avastin …
• Takeda Pharmaceutical Co. Ltd.
Ovarian Cancer Drugs Market Segmentation …
-
Avutometinib/Defactinib Display Safety, Efficacy in Ovarian Cancer Subtype
15 Jul 2025 21:16 GMT
… treated with prior bevacizumab (Avastin) vs 43% (95% CI … John Hayslip, MD, chief medical officer at Verastem Oncology, … RAMP 301 (NCT06072781) trial of the combination in … acneiform (4%). Additionally, treatment-related increased creatine phosphokinase (CPK …
-
Non-Small Cell Lung Cancer Market: Valued at $18.8 Billion in 2024, Expected to Grow at 6.9% CAGR Through 2035
15 Jul 2025 07:59 GMT
… China's National Medical Products Administration (NMPA) … FDA approval for Jobevne (bevacizumab-nwgd), a biosimilar to Avastin … Biotechnology revealed that it’s targeted CD228 antibody-drug … CROWN trial comparing LORBRENA with XALKORI in the treatment of …
-
PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer
13 Jul 2025 14:00 GMT
… (Tecentriq) and bevacizumab (Avastin), according to a presentation … , Xi’an International Medical Center Hospital, in China … of AEs related to treatment. Treatment-related grade 3 … research grants from Shanghai Roche Pharmaceuticals, Co. Ltd; Bayer; …
-
PD-L1 and HRD Correlation Shows Prognostic Value in Ovarian Cancer
10 Jul 2025 20:12 GMT
… olaparib (Lynparza) plus bevacizumab (Avastin) in newly diagnosed patients … trials combining immunotherapy with PARP inhibitors or antiangiogenic agents.
Additional Trial …
2. FDA approves olaparib plus bevacizumab as maintenance treatment for ovarian …
-
Anti-Angiogenesis Plus ICIs, Chemo Improve Frontline Efficacy in ES-SCLC
09 Jul 2025 20:24 GMT
… controlled trials (INPLASY2023110061) published in Therapeutic Advances in Medical Oncology. … regimen surpassed all alternative treatments, achieving the highest … atezolizumab (Tecentriq)-bevacizumab (Avastin)-chemotherapy exhibited increased PFS relative …
-
Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in nAMD and DME Management, According to Spherix Global Insights
10 Jul 2025 17:27 GMT
… increasingly competitive and complex treatment landscape for neovascular … second line product, after Avastin, due to its long … begin to require biosimilar trials before branded biologic access … expect a fundamentally reshaped treatment landscape within the next …
-
Oncologist explains the subtle signs of 'silent killer' ovarian cancer
15 Jul 2025 12:02 GMT
… out for them. Medical professionals and ovarian cancer … (Image: MAXWELLS DUBLIN)
Treatment “Treatment usually involves surgery and … a drug called Avastin for that. There’s another drug … better prognosis. “The treatments are continually improving too, …
About
© 1995-2025